DRTS Stock Touches 52-Week High at $3.43 Amid Sector Growth

In a notable surge, shares of Alpha Tau Medical (TASE:PMCN) Ltd. (DRTS) reached a 52-week high, trading at $3.43. The company, with a market capitalization of $238 million, has demonstrated remarkable momentum with a 52% gain over the past six months. According to InvestingPro analysis, technical indicators suggest the stock is in overbought territory, while analyst price targets range from $5 to $13, indicating potential upside. The company, operating within the dynamic healthcare sector, has shown resilience and growth potential, reflecting a positive sentiment among investors. With a strong current ratio of 10.99, the company maintains robust liquidity. Over the past year, the broader Healthcare Capital market has witnessed a modest uptick, with a 1-year change of 3.4%. This growth trajectory for Alpha Tau Medical Ltd. underscores a period of strategic advancements and investor confidence, as the stock carves out new peaks in its trading range. Get access to 8 additional key technical and fundamental insights with InvestingPro.

In other recent news, Alpha Tau Medical has been maintaining a positive outlook with several analyst firms. Piper Sandler upheld its Overweight rating on Alpha Tau Medical shares, highlighting the company's better-than-expected third-quarter operating loss of $8.3 million, compared to the projected $9.5 million. Alpha Tau Medical's clinical advancements were also noted, particularly the expected completion of enrollment for the U.S. pivotal trial by the first half of 2025.

Simultaneously, H.C. Wainwright reiterated its Buy rating on Alpha Tau Medical shares, following the initiation of a new clinical trial where the first patient with recurrent lung cancer was treated using Alpha DaRT in Jerusalem, Israel. The trial aims to test the safety and feasibility of delivering Alpha DaRT sources into the lung through an endobronchial ultrasound procedure.

In addition to these developments, Alpha Tau Medical reported a lower than expected second-quarter net loss of $7.4 million. The company's ReSTART U.S. pivotal trial for recurrent cutaneous squamous cell carcinoma and the Canadian trial for advanced inoperable pancreatic cancer are progressing as planned. Both analyst firms highlighted the company's efficient financial management and the progression of clinical trials.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.